Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AMN006 - Phase 2 Study of Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients

NCT03695744 is registered in ClinicalTrials.gov with Singapore General Hospital as lead sponsor.

NCT NCT03695744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03695744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AMN006 - Phase 2 Study of Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
Lead sponsor
Singapore General Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 2, 2019
Completion date
April 30, 2024
Enrollment
27 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, myeloma